Tharimmune Inc (THAR)

May 6, 2025, 8:01 AM EDT - 4 weeks ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 1, 2025, 8:01 AM EDT - 5 weeks ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Apr 30, 2025, 8:01 AM EDT - 5 weeks ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 28, 2025, 8:01 AM EDT - 5 weeks ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 15, 2025, 9:00 AM EDT - 7 weeks ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 7, 2025, 8:00 AM EDT - 2 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Mar 31, 2025, 8:00 AM EDT - 2 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 24, 2025, 8:00 AM EDT - 2 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 4, 2025, 7:00 AM EST - 3 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Jan 27, 2025, 8:30 AM EST - 4 months ago

Tharimmune to Present at the Microcap Conference 2025

Dec 16, 2024, 8:00 AM EST - 6 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 6, 2024, 4:15 PM EST - 6 months ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Nov 18, 2024, 8:00 AM EST - 7 months ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 13, 2024, 8:00 AM EST - 7 months ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 4, 2024, 9:00 AM EST - 7 months ago

Tharimmune Announces Upcoming Conference Presentations

Oct 30, 2024, 8:00 AM EDT - 7 months ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 28, 2024, 9:00 AM EDT - 7 months ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Sep 30, 2024, 7:00 AM EDT - 8 months ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 16, 2024, 7:00 AM EDT - 9 months ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Jul 22, 2024, 8:30 AM EDT - 11 months ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 17, 2024, 8:30 AM EDT - 11 months ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Feb 20, 2024, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 5, 2024, 8:30 AM EST - 1 year ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Jan 29, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Dec 11, 2023, 8:01 AM EST - 1 year ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Nov 30, 2023, 4:01 PM EST - 1 year ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 1 year ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 8:00 AM EST - 1 year ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 17, 2023, 7:00 AM EST - 1 year ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 6, 2023, 5:35 PM EST - 1 year ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Sep 22, 2023, 8:30 AM EDT - 1 year ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 11, 2023, 11:51 AM EDT - 1 year ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 8, 2023, 2:30 PM EDT - 1 year ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Aug 9, 2023, 8:47 AM EDT - 1 year ago

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

Jul 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Jul 6, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

May 15, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 2, 2023, 4:05 PM EDT - 2 years ago

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

Apr 27, 2023, 9:50 PM EDT - 2 years ago

Hillstream BioPharma Announces Pricing of Public Offering

Apr 27, 2023, 4:00 PM EDT - 2 years ago

Hillstream BioPharma Announces Proposed Public Offering

Apr 13, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism

Apr 12, 2023, 10:30 AM EDT - 2 years ago

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow

Apr 10, 2023, 8:47 AM EDT - 2 years ago

Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data